Creating an artificial immune system to deal with Psuedomonas aeruginosa’s biofilm. Mark Ly, Fahima Nakitende , Shannon Wesley. Human cystic fibrosis . Recessive genetic disorder Excess secretion Mucous Sweat Bacterial infection Pseudomonas aeruginosa.
Creating an artificial immune system to deal with Psuedomonasaeruginosa’sbiofilm
Mark Ly, FahimaNakitende, Shannon Wesley
Fig. 1. Age distribution of the Canadian CF population for 2008.
Fig. 2. Biofilm formation
Wires with a diameter in the nanometer scale
A group of nanowires
Large surface area
Used as detectors inbioelectrochemistry
Fig. 3. Transmission electron microscopy of Cu(OH)2 nanowires (Zhuang et al. 2007)
Fig. 4. Image of ordered nanowire in a microarray.
Emulate our immune system with nanowire bundles couple with antibiotics:Ciprofloxacin and Tobramycin
Use this net on biofilms to get through the slime layer more effectively.
Fig. 5. Image of a neutriphil net trapping bacteria
Following experimental design done by Li et al.
Self assembled nanowire bundles
Use of Heavy metals
Use of antibiotics
Use of Ciprofloxacin and Tobramycin antibiotics (Walters et al., 2003)
Slow diffusion of tobramycin due to binding
Oxygen may be limiting factor.
Metal cations (Harrison et al., 2005)
Cobalt, copper, nickel, silver.
High concentrations needed
Long continuous exposure time
Fig. 6. Log killing of biofilm cultures with increasing concentration of Copper ions over a 27 hour period. (Harrison et al., 2005).
Tobramycin slower than ciprofloxacin
Lack of oxygen restricts bacterial metabolic activity
Took long to penetrate through the biofilm
Fig. 7. Penetration of tobramycin (squares) and ciprofloxacin (circles) in P. aeruginosa. Open symbols are in sterile controls (Walters et al., 2003)
Fig. 8. Killing of P. aeruginosain biofilms in exposure to ciprofloxacin. Filled squares were the treatment and the unfilled were the controls (Walter et al.)
Fig. 9. Killing of P. aeruginosain biofilms in exposure to tobramycin. Filled squares were the treatment and the unfilled were the controls.
Fig. 10. Comparative percentage of the types of bacterial infections in CF patients in 2007 and 2008.